Mounjaro vs. Zepbound
Gleiches Tirzepatid — Unterschiedliche Zulassung & Kostenübernahme
Mounjaro und Zepbound sind dasselbe Medikament: Tirzepatid von Eli Lilly. Mounjaro ist für Typ-2-Diabetes zugelassen, Zepbound für Gewichtsmanagement. Dosierung und Wirkung sind identisch. Tracken Sie beides in Shotlee.
Mounjaro vs. Zepbound auf einen Blick
- →Zulassung: Typ-2-Diabetes Management
- →Dosisstufen: 2,5 mg bis 15 mg wöchentlich
- →Senkt HbA1c signifikant (−2,3%)
- →Wird oft Off-Label zur Gewichtsreduktion verschrieben
- →Krankenkasse: Übernahme bei T2D oft möglich
- →Zulassung: Chronisches Gewichtsmanagement
- →Zusatz-Zulassung: Schlafapnoe (2024)
- →~21% Gewichtsverlust in Studien (SURMOUNT-1)
- →Identische Dosierung wie Mounjaro
- →Krankenkasse: In DE meist Selbstzahler-Leistung
Wichtige Zahlen
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Active molecule | Tirzepatide | TirzepatideBest |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA indication | Type 2 diabetes | Obesity + obstructive sleep apnea |
| Dose range | 2.5–15 mg weekly | 2.5–15 mg weekly |
| Dose escalation | Same 4-week steps | Same 4-week steps |
| Weight loss data | ~22% at 15 mg (SURMOUNT-4 T2D) | ~20.9% at 15 mg (SURMOUNT-1 obesity) |
| Sleep apnea approval | No | Yes (2024) |
| T2D insurance coverage | Usually covered | Usually not covered |
| Obesity insurance coverage | Off-label only | Covered if qualifying |
| Monthly cost (uninsured) | ~$1,000–1,200 | ~$1,000–1,200 (autoinjector); lower via Lilly vials |
Warum gibt es zwei Namen?
Choose Based on Your Goal
You have type 2 diabetes
Mounjaro is the T2D-approved brand with strong SURPASS trial data. Most T2D insurance plans cover it; your endocrinologist will typically prescribe Mounjaro.
Weight loss is the primary goal
Zepbound is specifically dosed and approved for obesity. SURMOUNT-1 showed 20.9% mean weight loss — the highest of any approved obesity drug.
Obstructive sleep apnea
Zepbound gained the first-ever FDA approval specifically for obstructive sleep apnea in 2024. Mounjaro does not have this indication.
Insurance covers T2D but not obesity
Mounjaro is often prescribed off-label for weight loss when the plan does not cover Zepbound. Same drug, different label.
Cost for self-pay patients
Eli Lilly launched lower-cost Zepbound single-dose vials specifically for self-pay patients. Check Lilly's direct pharmacy programme for current pricing.
Switching between them
Switching from Mounjaro to Zepbound (or vice versa) requires no dose adjustment — it is literally the same drug. Update your prescription brand in Shotlee.
Why Two Brand Names?
Pharmaceutical companies seek separate FDA approvals for different indications — even when the drug is identical. This allows them to market the product to different specialties (endocrinology vs obesity medicine), negotiate insurance coverage separately, and set different formulary positions. The pharmacology is completely unchanged.
Zepbound gained an additional approval in 2024 for obstructive sleep apnea — the first medication ever specifically approved for this condition — making it the more versatile option for patients with multiple weight-related conditions.
If you have type 2 diabetes, your doctor will typically prescribe Mounjaro for better insurance coverage. If your primary goal is weight loss or you have sleep apnea, Zepbound is the on-label choice. In practice, the drugs are interchangeable — the brand name determines coverage.
Mounjaro vs Zepbound: Häufig gestellte Fragen
Ja, der Wirkstoff Tirzepatid ist in beiden Produkten in identischer Konzentration enthalten.
Ja, viele Ärzte verschreiben es dafür, da Zepbound in einigen Märkten (wie Deutschland) noch nicht unter diesem Namen flächendeckend verfügbar ist.
Mounjaro oder Zepbound in Shotlee tracken
Vollständige Verfolgung der Dosiseskalation von 2,5–15 mg, Injektionserinnerungen und Gewichtskurven. Kostenlos.